NCT06535854ClinicalTrials.gov
Prevail Global Study
A Randomized Controlled Study of the Prevail Drug-Coated Balloon in Subjects With In-stent Restenosis and a Single Arm Prospectively Enrolled Study of the Prevail Drug-Coated Balloon for de Novo Lesions in Small Vessel Disease (Prevail Global).
En bref
The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.
Interventionnelle1 205 participants recherchés79 sites9 pays
Catégories
Enregistré dans 1 registre
- ClinicalTrials.govNCT06535854Ouvrir cette fiche sur ClinicalTrials.govSynchronisé il y a 4 semaines
Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.
Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.
Cette étude vous intéresse ?
Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2024-08-02; recorded start 2025-02-24
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 10 other studies in this databaseCounted from the lead sponsor named in the record (Medtronic Vascular)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a study of this type, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding7/20
Single-blind
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 51 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study, international in scope: 1,205 participants (target), run at 79 sites, across 9 countries.
How this score is built
- Enrolment31/40
1,205 participants (target)
- Site count20/25
51 sites
- Country count0/15
Single country
- Planned duration10/10
Planned over about 72 months
- Sponsor scale3/10
Medtronic Vascular has led 11 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Résumé
The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.
Affections
- Coronary Artery Disease
Éligibilité
| Sexe | Tous |
|---|---|
| Âges | 18 Years – Aucun maximum |
| Volontaires sains | Non |
Éligibilité telle qu'elle figure dans le registre
Éligibilité en énoncés simples
Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.
Conception de l'étude
| Type d'étude | Interventionnelle |
|---|---|
| Phase | Sans objet |
| Répartition | Randomisée |
| Modèle d'intervention | PARALLEL |
| Objectif principal | TREATMENT |
| Insu | SINGLE (1) |
| Recrutement | 1 205 participants recherchés |
Promoteur et collaborateurs
- Medtronic Vascular Promoteur
Groupes et interventions
- ISR Cohort Prevail DCBEXPERIMENTAL
To evaluate the clinical safety and efficacy of the Prevail DCB in the treatment of ISR with coronary lesions previously treated with drug-eluting or bare metal stents in native coronary arteries.
- DNSV Cohort (RVD 2.0 - 2.75mm)EXPERIMENTAL
To evaluate the clinical safety and efficacy of the Prevail DCB as compared to a DES historical control in subjects undergoing PCI for de novo lesions in small vessel disease.
Interventions
- Dispositif Agent DCB
The Agent Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR).
- Dispositif Prevail DCB
The Prevail Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR) and to treat de novo lesions in small vessel disease.
Critères de jugement
Critère de jugement principal
ISR Cohort Primary Analysis
The TLF rate of the Prevail DCB arm at 12 months post procedure compared to the Agent DCB arm for non-inferiority
Délai 1 year post-procedure
Critère de jugement principal
DNSV Cohort Primary Analysis
The TLF rate of the Prevail DCB arm at 12 months post procedure compared to a DES historical control
Délai 1 year post-procedure
Critère de jugement secondaire
Acute success
Acute success (device, lesion, and procedure) through hospital discharge only
Délai hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Critère de jugement secondaire
All deaths
Délai hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Critère de jugement secondaire
Cardiac death
Délai hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Critère de jugement secondaire
All myocardial infarction (MI), including target vessel myocardial infarction (TVMI)
Délai hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Critère de jugement secondaire
Clinically-driven target lesion revascularization (cd-TLR) defined as repeat PCI or CABG to the target lesion
Délai hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Critère de jugement secondaire
Clinically-driven target vessel revascularization (cd-TVR)
Délai hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Critère de jugement secondaire
Major adverse cardiac event (MACE) defined as composite of death, MI, or repeat cd-TLR
Délai hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Critère de jugement secondaire
Target lesion failure (TLF) defined as composite of cardiac death, TVMI, or cd-TLR
Délai hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Critère de jugement secondaire
Target vessel failure (TVF) defined as composite of cardiac death, TVMI, or cd-TVR
Délai hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Critère de jugement secondaire
Target lesion thrombosis (TLT) (definite or probable) according to Academic Research Consortium (ARC) definition
Délai hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Dates
| Date de début | 24 février 2025 (réelle) |
|---|---|
| Achèvement principal | 1 février 2027 (estimée) |
| Achèvement | 1 février 2031 (estimée) |
| Première publication | 2 août 2024 (réelle) |
| Dernière mise à jour | 21 octobre 2026 |
| Résultats publiés | Non précisé dans la fiche du registre |
| Statut vérifié pour la dernière fois | octobre 2026 |
Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.
Lieux
78 sites sont en recrutement
Canada
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Montreal Heart Institute | Montreal | En recrutement | |
| Hôpital du Sacre Coeur de Montreal | Montreal | En recrutement | |
| University of Ottawa Heart Institute | Ottawa | En recrutement | |
| Toronto General Hospital | Toronto | En recrutement | |
| Vancouver General Hospital | Vancouver | En recrutement |
Germany
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Herzzentrum Dresden GmbH Universitätsklinik | Dresden | En recrutement | |
| Universitat des Saarlandes | Homburg | En recrutement | |
| MediClin Herzzentrum Lahr / Baden | Lahr | En recrutement |
Hong Kong
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Queen Mary Hospital | Hong Kong | En recrutement |
Ireland
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Mater Private Network | Dublin | En recrutement | |
| Galway University Hospitals - University Hospital Galway (UHG) | Galway | En recrutement |
Japan
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Teikyo University Hospital | Itabashi-ku | Tokyo | En recrutement |
| Shonan Kamakura General Hospital | Kamakura | Kanagawa | En recrutement |
| Kokura Memorial Hospital | Kitakyushu | Fukuoka | En recrutement |
| Sendai Kousei Hospital | Sendai | Miyagi | En recrutement |
| Saiseikai Yokohamashi Tobu Hospital | Yokohama | Kanagawa | En recrutement |
Singapore
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Sengkang General Hospital | Singapore | En recrutement | |
| Tan Tock Seng Hospital | Singapore | En recrutement |
South Korea
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Keimyung University Dongsan Hospital | Daegu | En recrutement | |
| Korea University Anam Hospital | Seoul | En recrutement | |
| Seoul Saint Marys Hospital | Seoul | En recrutement | |
| Seoul National University Hospital | Seoul | En recrutement | |
| Asan Medical Center | Seoul | En recrutement |
United Kingdom
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| The Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital | Newcastle upon Tyne | En recrutement |
United States
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Lehigh Valley Hospital - Cedar Crest | Allentown | Pennsylvania | En recrutement |
| AnMed Health Medical Center | Anderson | South Carolina | En recrutement |
| University of Michigan Health System - University Hospital | Ann Arbor | Michigan | En recrutement |
| Emory University Hospital Midtown | Atlanta | Georgia | En recrutement |
| Piedmont Atlanta Hospital | Atlanta | Georgia | En recrutement |
| The University of Alabama at Birmingham | Birmingham | Alabama | En recrutement |
| Cardiology P.C. | Birmingham | Alabama | En recrutement |
| Kaleida Health | Buffalo | New York | En recrutement |
| Virtua Our Lady of Lourdes Hospital | Camden | New Jersey | En recrutement |
| Medical University of South Carolina (MUSC) | Charleston | South Carolina | En recrutement |
| Advocate Illinois Masonic Medical Center | Chicago | Illinois | En recrutement |
| The Lindner Research Center | Cincinnati | Ohio | En recrutement |
| BayCare Health System | Clearwater | Florida | En recrutement |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | En recrutement |
| OhioHealth Riverside Methodist Hospital | Columbus | Ohio | En recrutement |
| Baylor Heart & Vascular Hospital | Dallas | Texas | En recrutement |
| Saint Elizabeth Healthcare | Edgewood | Kentucky | En recrutement |
| M Health Fairview Clinic | Edina | Minnesota | Retiré |
| Parkview Health | Fort Wayne | Indiana | En recrutement |
| North Florida Regional Medical Center | Gainesville | Florida | En recrutement |
| Corewell Health | Grand Rapids | Michigan | En recrutement |
| The Moses H Cone Memorial Hospital | Greensboro | North Carolina | En recrutement |
| UPMC Pinnacle Harrisburg Campus | Harrisburg | Pennsylvania | En recrutement |
| HCA Houston Medical Center | Houston | Texas | En recrutement |
| Huntsville Hospital | Huntsville | Alabama | En recrutement |
| Saint Lukes Mid America Heart Institute | Kansas City | Missouri | En recrutement |
29 sites supplémentaires sont indiqués dans la fiche du registre.
Documents de l'étude
Aucun document n'est lié dans cette fiche du registre.
Évolution au fil du temps
- 21 octobre 2026
Site ajouté
28 sites added (79 total)
5179